Literature DB >> 15456839

Cellular G protein-coupled receptor kinase levels regulate sensitivity of the {alpha}2b-adrenergic receptor to undergo agonist-induced down-regulation.

Aarti N Desai1, Kelly M Standifer, Douglas C Eikenburg.   

Abstract

Chronic coactivation of alpha(2B)- and beta(2)-adrenoceptors (AR) was recently reported to down-regulate the alpha(2B)-AR at a lower threshold epinephrine (EPI) concentration compared with the activation of alpha(2B)-AR alone. This is the result of a modest beta(2)-AR-dependent up-regulation of G protein-coupled receptor kinase 3 (GRK3). In the present study, we determined that increasing GRK2 or GRK3 levels, independent of beta(2)-AR activation, decreases the EC(50) concentration for agonist-induced down-regulation of the alpha(2B)-AR using NG108 cells with or without overexpression (2- to 10-fold) of GRK2 or GRK3. In parental NG108 cells, the EC(50) concentration of EPI required for down-regulation of the alpha(2B)-AR is 30 microM. A 2- to 3-fold overexpression of GRK3 in NG108 cells, however, reduces the EC(50) to 0.2 microM (a 150-fold decrease), whereas a comparable overexpression of GRK2 reduces it to 1 microM (a 30-fold decrease). However, when GRK3 or GRK2 in NG108 cells are overexpressed 8- to 10-fold, the EC(50) concentration (0.02 microM EPI) for alpha(2B)-AR down-regulation is reduced 1000-fold. These data clearly suggest that a modest (2- to 3-fold) up-regulation of GRK3 is more effective at enhancing the sensitivity of alpha(2B)-AR to down-regulation after exposure to EPI than a modest up-regulation of GRK2, but that both GRK2 and GRK3 are equally effective at inducing alpha(2B)-AR down-regulation when up-regulated 8- to 10-fold. To our knowledge, this is the first report to systematically demonstrate that GRKs, particularly GRK3, play a pivotal role in modulating the agonist EC(50) concentration that down-regulates the alpha(2B)-AR and thus adds a new dimension to an already intricate signaling network.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456839     DOI: 10.1124/jpet.104.076042

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  4 in total

1.  Involvement of α2- and β2-adrenoceptors on breast cancer cell proliferation and tumour growth regulation.

Authors:  C Pérez Piñero; A Bruzzone; M G Sarappa; L F Castillo; I A Lüthy
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Differential effects of inescapable stress on locus coeruleus GRK3, alpha2-adrenoceptor and CRF1 receptor levels in learned helpless and non-helpless rats: a potential link to stress resilience.

Authors:  Manish Taneja; Samina Salim; Kaustuv Saha; H Kevin Happe; Nidal Qutna; Frederick Petty; David B Bylund; Douglas C Eikenburg
Journal:  Behav Brain Res       Date:  2011-02-17       Impact factor: 3.332

3.  Chronic adrenaline treatment fails to down-regulate the Del301-303-alpha2B-adrenoceptor in neuronal cells.

Authors:  S Salim; A N Desai; M Taneja; D C Eikenburg
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

4.  The presence of beta2-adrenoceptors sensitizes alpha2A-adrenoceptors to desensitization after chronic epinephrine treatment.

Authors:  Tasneem Bawa-Khalfe; Ghazi F Altememi; Chitra D Mandyam; Lindsay A Schwarz; Douglas C Eikenburg; Kelly M Standifer
Journal:  BMC Pharmacol       Date:  2007-12-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.